Source: International Congress 2015 – Advances from translational research in respiratory infections
Disease area: Respiratory infections

Abstract

Bronchiectasis is characterised by persistent infection resulting in permanent damage to the lungs, leading to increased morbidity and mortality. In genetic forms of bronchiectasis such as Cystic Fibrosis (CF) Pseudomonas aeruginosa (PA) infections reduce life expectancy in CF patients. In CF epidemic PA strains are associated with poorer outcomes. Persistent infection with PA in NCFBr is adversely prognostic but significant studies of PA biology and epidemic strains are lacking in NCFBr. The aim of this project is to address this extending work from De Soyza et al ERJ 2014.Methods Array Tube genotyping on isolates from a PA collection obtained from 56 patients (2007 – 2014) attending an adult NCFBr centre, Newcastle UK cross-sectionally and longitudinally in 11 patients. We studied PA isolates using specific PCR for 3 common UK transmissible strains.Results Although most PA were identified as unique clones, some common PA clones were identified in multiple patients. PCR screening for 3 common UK transmissible strains revealed the presence of the Midlands-1 Epidemic strain in only one patient. Longitudinal screening demonstrated that 9 patients out of 11 retained the same infecting strain for a period of 3 to 35 months.Conclusions and future work We have identified that epidemic strains are rare in NCFBr but that epidemic strains can infect NCFBr patients. These data provide insights to the PA biology in NCFBr. We will use whole genome sequencing to further study the P. aeruginosa population structure in NCFBr and how these populations change over time during lung infections. A Multi –centre study across 9 sites in the UK is underway.


Rating:

Share or cite this content

Citations should be made in the following way:
Anthony De Soyza (Newcastle upon Tyne, United Kingdom), Y.K. Hilliam, A. Perry, A.J. Hall, J. Davison, K.E. Walton, J. Fothergill, A. De Soyza, C. Winstanley. Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients. Eur Respir J 2015; 46: Suppl. 59, 5039

Member's Comments

No comment yet.

Related content which might interest you: Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002 Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Host specificity of pseudomonas aeruginosa isolates from patients with cystic fibrosis and patients from different clinical backgrounds Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa: Role of inhaled colistin Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors? Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Pseudomonas aeruginosa infections Source: Respipedia Article Year: 2018 Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis Source: ERJ Open Res, 4 (2) 00162-2017; 10.1183/23120541.00162-2017 Year: 2018 Temperate bacteriophages of pseudomonas aeruginosa as markers of bacterial adaptation in CF and non-CF bronchiectasis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 LATE-BREAKING ABSTRACT: Pseudomonas aeruginosa strain prevalence, adaptation and diversification, during chronic lung infections of UK non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Molecular epidemiological analysis suggests cross-infection with Pseudomonas aeruginosa is rare in non-cystic fibrosis bronchiectasis Source: Eur Respir J 2014; 43: 900-903 Year: 2014 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients Source: Eur Respir J 2006 Oct 01;28(4):740-747 Year: 2006 Eradication of Pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2006; 27: 653 Year: 2006 Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections Source: Eur Respir J 2012; 40: 227-238 Year: 2012